From 1/1-4/15, $9M cash raised via warrants. No offering until January 2020!


IDMC NEWS

IDMC SAYS KEEP TRUCKIN'!

image613

Press Release from March 29th stating the trial should continue on!

IDMC Sees

image614

The IDMC knows how the LARGEST Head and Neck Cancer Study is progressing.


AND THEY SAID CONTINUE ON!


To Resist Is FUTILE!

image615

You read that right.  Interim analysis is done to DETERMINE FUTILITY.  Tested and tested again!


It would have been deemed futile if Multikine wasn't extending survival over standard care by 10% or more!


Guess, what?  As recent as March 29, 2019 the IDMC determined the LARGEST Head and Neck Trial wasn't Futile after all these years.

THE IDMC NEVER DETERMINES A STUDY IS FUTILE?! BULLSHIT!!!!!

They SHUT 'EM DOWN all the time.


On April 12, 2019 The IDMC shut down TWO TRIALS!!!


 Tracon Pharmaceuticals trial


 "Tracon Pharmaceuticals Inc. shares TCON, -49.24% slid 45% in premarket trade Friday, after the company said it is terminating a late-stage trial of a cancer treatment at the recommendation of an independent committee. The company said its phase 3 trial evaluating TRC105 in combination with Votrient in patients with advanced or metastatic angiosarcoma, a rare kind of cancer, was terminated for futility based on the recommendation of the Independent Data Monitoring Committee following a review of data from more than 120 patients. "


PRESS RELEASE HERE


AND

Clovis Oncology

 

"Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent.

The company said its decision to discontinue the trial was based on recommendations of an independent committee, which suggested that the treatment may not provide a meaningful benefit to patients."


PRESS RELEASE HERE



On March 22, 2019 The IDMC shut down BIOGEN's Alzheimer's Study


 "Biogen BIIB and its Japan-based partner Eisai announced the discontinuation of two late-stage studies evaluating their Alzheimer’s disease candidate, aducanumab. The decision was taken following a futility analysis conducted by an independent data monitoring committee (“IDMC”). The analysis showed that the studies are unlikely to meet their primary endpoints."


PRESS RELEASE HERE